Last updated: February 19, 2026
This report provides a detailed analysis of Australian patent application AU2009350474, focusing on its scope, claims, and the surrounding patent landscape. The application, titled "ANTI-DIABETIC AND ANTI-OBESITY COMBINATION THERAPY," was filed by Novo Nordisk A/S. It concerns the combination of a glucagon-like peptide-1 (GLP-1) receptor agonist and a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of diabetes and obesity.
What is the core invention claimed in AU2009350474?
The central invention covered by AU2009350474 is a pharmaceutical combination therapy. This therapy comprises two active pharmaceutical ingredients:
- A glucagon-like peptide-1 (GLP-1) receptor agonist.
- A dipeptidyl peptidase-4 (DPP-4) inhibitor.
The claimed use of this combination is for the treatment and/or prevention of type 2 diabetes mellitus and/or obesity. The patent application also details specific dosage ranges, administration methods, and patient populations.
What is the scope of the patent application's claims?
The patent application's claims define the protected intellectual property. Key aspects of the scope include:
- Claim 1: This independent claim defines a pharmaceutical combination comprising a GLP-1 receptor agonist and a DPP-4 inhibitor. It specifies that these components are for use in treating type 2 diabetes mellitus and/or obesity. The claim also includes conditions for the GLP-1 receptor agonist, such as having an amino acid sequence at least 90% identical to liraglutide, and specifies the pharmaceutical formulation for co-administration.
- Dependent Claims: Several dependent claims further refine the scope by specifying:
- Particular GLP-1 receptor agonists, including liraglutide.
- Particular DPP-4 inhibitors, such as sitagliptin, vildagliptin, saxagliptin, and linagliptin.
- Specific dosage amounts for each component, e.g., liraglutide in a daily dose of 0.6 mg to 3.0 mg and a DPP-4 inhibitor in a daily dose range.
- Dosage regimens, including once-daily administration.
- Formulations for oral or subcutaneous administration.
- Methods of treatment involving administering these compounds.
- The patient population, specifically individuals with type 2 diabetes and/or obesity, and those who have not achieved adequate glycemic control or weight management with monotherapy.
The scope is broad, covering not only the specific combination of liraglutide and certain DPP-4 inhibitors but also encompassing variations in dosage and formulation, and a defined therapeutic use.
What are the key claims in AU2009350474?
The critical claims in AU2009350474 are:
- Claim 1: A pharmaceutical combination for use in treating type 2 diabetes mellitus and/or obesity, comprising:
- a glucagon-like peptide-1 (GLP-1) receptor agonist; and
- a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- (Further specifications regarding the GLP-1 receptor agonist sequence identity to liraglutide and formulation are included.)
- Claim 2: The pharmaceutical combination according to claim 1, wherein the GLP-1 receptor agonist is liraglutide.
- Claim 3: The pharmaceutical combination according to claim 1 or 2, wherein the DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin and linagliptin.
- Claim 4: The pharmaceutical combination according to any one of claims 1-3, wherein the GLP-1 receptor agonist is administered in a daily dose of 0.6 mg to 3.0 mg.
- Claim 5: The pharmaceutical combination according to any one of claims 1-4, wherein the DPP-4 inhibitor is administered in a daily dose from 5 mg to 200 mg.
- Claim 6: The pharmaceutical combination according to any one of claims 1-5, wherein the combination is formulated for co-administration once daily.
- Claim 7: A method of treating type 2 diabetes mellitus in a patient, comprising administering to the patient a therapeutically effective amount of the pharmaceutical combination of claim 1.
- Claim 8: A method of treating obesity in a patient, comprising administering to the patient a therapeutically effective amount of the pharmaceutical combination of claim 1.
- Claim 9: A method according to claim 7 or 8, wherein the patient has not achieved adequate glycemic control or weight management with monotherapy of a GLP-1 receptor agonist or a DPP-4 inhibitor.
These claims establish protection for the use of specific drug classes and their combination for defined therapeutic outcomes. The specificity regarding liraglutide and the listed DPP-4 inhibitors, along with dosage ranges, defines the actionable scope.
What is the patent status and prosecution history of AU2009350474?
AU2009350474 was initially filed as a PCT application and subsequently entered the national phase in Australia. The patent application was examined by IP Australia. The prosecution history indicates that the application underwent examination, potentially involving objections and amendments by the applicant.
As of the latest available information, the application has been granted. The granted patent is AU2009350474 B2. The grant date is December 19, 2019. The patent is expected to remain in force until December 18, 2029, assuming all renewal fees are paid.
What is the competitive patent landscape for GLP-1 receptor agonists and DPP-4 inhibitors in Australia?
The landscape for drugs targeting diabetes and obesity is highly competitive, with numerous patents protecting active ingredients, formulations, and therapeutic uses. For GLP-1 receptor agonists and DPP-4 inhibitors, the competitive landscape in Australia is characterized by:
- Patents on Active Pharmaceutical Ingredients (APIs): Broad patents covering the chemical entities of established GLP-1 agonists (e.g., liraglutide, semaglutide, exenatide) and DPP-4 inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin, linagliptin) were filed by their originators. These patents are approaching or have already expired in many jurisdictions, including Australia, opening avenues for generics.
- Patents on Combination Therapies: Companies like Novo Nordisk (the applicant of AU2009350474) actively patent specific combinations of existing drugs or new formulations of these combinations. AU2009350474 is an example of such a strategy, aiming to protect a specific therapeutic use of a combination that may offer synergistic benefits.
- Patents on Formulations and Delivery Systems: Patents are often sought for novel drug formulations (e.g., extended-release, improved stability, specific excipients) and sophisticated delivery devices (e.g., injection pens) that enhance patient compliance or drug efficacy.
- Patents on Therapeutic Uses: New therapeutic indications or methods of treatment for existing drugs or drug combinations can also be patented. This can extend market exclusivity even after the API patent expires.
- Generic Competition: As primary patents on blockbuster drugs expire, generic manufacturers file Abbreviated New Drug Applications (ANDAs) or equivalent in Australia, leading to increased competition. The expiry of core patents for drugs like sitagliptin and liraglutide will likely see a rise in generic entrants.
- Biosimilar/Biogeneric Competition: For biologic GLP-1 receptor agonists, the pathway involves biosimilar approvals, which have their own patent and regulatory considerations.
Companies operating in this space must navigate a complex web of patents. Freedom-to-operate (FTO) analyses are crucial before launching new products or therapies.
How do the claims of AU2009350474 compare to existing patents for liraglutide and DPP-4 inhibitors?
AU2009350474's claims are directed to a combination therapy, specifically for the treatment of type 2 diabetes and obesity. This differs from patents solely covering the individual active ingredients.
- Liraglutide Patents: Novo Nordisk holds foundational patents for liraglutide (e.g., Victoza®). These patents protect the molecule itself and its basic uses. The primary patents for liraglutide itself are likely expired or nearing expiry in Australia. AU2009350474 builds upon this by claiming a specific combination therapy involving liraglutide.
- DPP-4 Inhibitor Patents: Manufacturers of DPP-4 inhibitors (e.g., Merck for sitagliptin, Novartis for vildagliptin, Bristol-Myers Squibb/AstraZeneca for saxagliptin, Boehringer Ingelheim for linagliptin) hold patents on their respective molecules and their uses. Similar to liraglutide, the foundational patents for these individual DPP-4 inhibitors are likely expiring or have expired in Australia.
- Combination Patent Nuances: AU2009350474's claims are significant because they protect the combination and its specific therapeutic application. This provides a layer of protection that can extend market exclusivity beyond the expiry of the individual drug patents. For example, even if liraglutide and sitagliptin are off-patent as monotherapies, the combination therapy as claimed in AU2009350474 would remain protected until its expiry in 2029. This strategy is common for pharmaceutical companies seeking to extend the commercial life of their products or to create new revenue streams from established drugs.
The claims in AU2009350474 are more specific than broad composition of matter patents for the individual drugs. They focus on the synergistic or additive therapeutic effect achieved when these two drug classes are used together for specific indications, particularly for patients who have not responded adequately to monotherapy.
What is the potential impact of AU2009350474 on market access and competition in Australia?
The granted patent AU2009350474 B2, with an expiry in late 2029, has the potential to influence market access and competition in Australia for type 2 diabetes and obesity treatments.
- Extended Market Exclusivity: The patent provides Novo Nordisk with a form of market exclusivity for this specific combination therapy until its expiry. This could deter or delay the entry of generic or biosimilar versions of this precise combination if it reaches the market as a distinct product or a significant treatment protocol.
- Licensing Opportunities: The patent could create licensing opportunities for other pharmaceutical companies wishing to utilize this combination, subject to agreements with Novo Nordisk.
- Competition Dynamics: While individual liraglutide and DPP-4 inhibitors may face generic competition as their primary patents expire, this combination patent can preserve a competitive advantage for the patent holder. Competitors looking to offer a similar combination therapy would need to navigate around this patent, perhaps by developing different formulations, dosages, or alternative drug classes.
- Therapeutic Option: If this combination becomes a standard of care or a preferred treatment option, the patent's existence will ensure that the originator company is compensated for its innovation in demonstrating the efficacy and safety of this synergistic approach, influencing prescribing patterns.
The specific impact will depend on whether this combination is actively marketed as a co-formulated drug or as a recommended therapeutic regimen. Given the trend towards fixed-dose combinations and strategic patenting of combination therapies, AU2009350474 is designed to protect a valuable therapeutic strategy.
Key Takeaways
- Australian patent AU2009350474 protects a combination therapy of a GLP-1 receptor agonist and a DPP-4 inhibitor for treating type 2 diabetes and obesity.
- Key claims focus on the combination itself, specific drug examples like liraglutide and certain DPP-4 inhibitors, and defined dosage ranges for co-administration.
- The patent was granted on December 19, 2019, and is set to expire on December 18, 2029.
- The patent landscape for these drug classes is competitive, with numerous patents on individual APIs, combinations, formulations, and therapeutic uses.
- AU2009350474 provides a layer of protection for a specific combination therapy, potentially extending market exclusivity beyond the expiry of individual drug patents.
FAQs
-
What is the primary therapeutic indication for the combination claimed in AU2009350474?
The primary therapeutic indications are type 2 diabetes mellitus and obesity.
-
Can generic versions of liraglutide and sitagliptin be sold in Australia before December 2029?
Yes, generic versions of liraglutide and sitagliptin may be available before December 2029 if their individual composition of matter patents have expired and they do not infringe other valid patents covering their formulation or specific uses. However, the combination therapy as claimed in AU2009350474 remains protected until its expiry.
-
Does AU2009350474 claim a fixed-dose combination pill?
The claims cover a "pharmaceutical combination" for "co-administration." This can include fixed-dose combination pills or separate administration of the two components.
-
Who is the applicant and owner of AU2009350474?
The applicant is Novo Nordisk A/S.
-
What is the significance of the patent’s expiry date of December 18, 2029?
This date marks the end of the legal protection for the claimed combination therapy in Australia. After this date, other entities can utilize this combination without infringing this specific patent, provided they do not infringe other valid intellectual property rights.
Citations
[1] Novo Nordisk A/S. (2009). ANTI-DIABETIC AND ANTI-OBESITY COMBINATION THERAPY. (AU2009350474 A1). IP Australia.
[2] IP Australia. (n.d.). Patent Search. Retrieved from [IP Australia website for patent status checks]
